| ZYME Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the ZYME shares outstanding history going back to 4/28/2017:
Also see: ZYME Market Cap History ZYME YTD Return |
ZYME Shares Outstanding History — Zymeworks Share Count Over Time
As of 5/6/2026 Zymeworks has 73.02 million ZYME shares outstanding. Investors often track the ZYME shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows ZYME share count trends over time, with 33 historical shares outstanding datapoints presented, dating back to 4/28/2017.
| ZYME Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ZYME Historical Shares Outstanding: +13.02% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ZYME Stock Price Chart |
| About Zymeworks Inc |
| Zymeworks Inc. is a global biotechnology company. Co. is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). We show 33 historical shares outstanding datapoints in our coverage of ZYME's shares outstanding history. Understanding the changing numbers of ZYME shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ZYME versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ZYME by allowing them to research ZYME shares outstanding history as well as any other stock in our coverage universe. |
| ZYME Current Stock Quote |
Quotes delayed 20 minutes  Free ZYME Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| ZYME Share Performance |
| Shares Outstanding Peers |
| Zymeworks (ZYME) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
ZYNE Shares Outstanding History ZYXI Shares Outstanding History A Shares Outstanding History AAC Shares Outstanding History AADI Shares Outstanding History AARD Shares Outstanding History ABAX Shares Outstanding History ABBV Shares Outstanding History ABC Shares Outstanding History ABEO Shares Outstanding History More Healthcare companies » |
ZYME Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
